Search research articles
Contact Us
Filters
Showing results (341-350 of 426) with videos related to
Page
of 43
Sort By:
Oncogene
|
September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
European Urology
|
October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
Joaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Jean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
European Urology
|
September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer
Yezi Zhu, Adam Sharp, Courtney M Anderson, et al.
European Urology
|
December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan M Basch, Mark Scholz, Johann S de Bono, et al.
The Lancet. Oncology
|
February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S de Bono, Nicole Concin, David S Hong, et al.
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Page
of 43
Search research articles
Search
Showing results (341-350 of 426) with videos related to
Sort By:
Page
of 43
Oncogene
|
September 12, 2024
AR coactivators, CBP/p300, are critical mediators of DNA repair in prostate cancer
Sumaira Sardar, Christopher M McNair, Lakshmi Ravindranath, et al.
European Urology
|
October 29, 2015
Prior Endocrine Therapy Impact on Abiraterone Acetate Clinical Efficacy in Metastatic Castration-resistant Prostate Cancer: Post-hoc Analysis of Randomised Phase 3 Studies
Joaquim Bellmunt, Thian Kheoh, Margaret K Yu, et al.
European Urology
|
April 10, 2022
Pembrolizumab Plus Docetaxel and Prednisone in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort B Study
Evan Y Yu, Michael P Kolinsky, William R Berry, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
June 19, 2015
Serial Next-Generation Sequencing of Circulating Cell-Free DNA Evaluating Tumor Clone Response To Molecularly Targeted Drug Administration
Jean Sebastien Frenel, Suzanne Carreira, Jane Goodall, et al.
Cancer Discovery
|
September 29, 2020
First-in-Human Trial of the Oral Ataxia Telangiectasia and RAD3-Related (ATR) Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Timothy A Yap, David S P Tan, Angelika Terbuch, et al.
European Urology
|
September 4, 2017
Novel Junction-specific and Quantifiable In Situ Detection of AR-V7 and its Clinical Correlates in Metastatic Castration-resistant Prostate Cancer
Yezi Zhu, Adam Sharp, Courtney M Anderson, et al.
European Urology
|
December 12, 2018
Cabozantinib Versus Mitoxantrone-prednisone in Symptomatic Metastatic Castration-resistant Prostate Cancer: A Randomized Phase 3 Trial with a Primary Pain Endpoint
Ethan M Basch, Mark Scholz, Johann S de Bono, et al.
The Lancet. Oncology
|
February 13, 2019
Tisotumab vedotin in patients with advanced or metastatic solid tumours (InnovaTV 201): a first-in-human, multicentre, phase 1-2 trial
Johann S de Bono, Nicole Concin, David S Hong, et al.
Cancer Discovery
|
June 14, 2025
Phase Ib basket expansion trial and alternative-schedule dose-escalation study of ATR inhibitor elimusertib in advanced solid tumors with DNA damage response defects
Timothy A Yap, David S P Tan, Anastasios Stathis, et al.
The Oncologist
|
April 24, 2025
Barriers to publishing early phase clinical trials: the oncologists' perspective
Merel J J Lucassen, Pedro Bergmann, Olga Husson, et al.
Page
of 43